The aim of the collaboration effort, known as Proof-of-Concept, is to help pharmaceutical companies use information integration to identify and capitalize on opportunities to reduce risk and increase operational efficiencies.
The IBM is the first demonstration of how complex solutions can be integrated with a compliance-centric architecture to transform a pharmaceutical organization’s development and manufacturing processes, said Doug Dean, senior executive, global quality and Value-Driven Compliance, IBM Healthcare and Life Sciences.
According to IBM, the Value-Driven Compliance Solutions framework is an initiative designed to help pharmaceutical companies improve manufacturing efficiencies, increase top-line growth and comply with government and systems-based regulations by focusing on designing quality into the manufacturing process rather than post-manufacturing inspection.
